Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan
In Pakistan, the burden of the hepatitis C virus (HCV) infection is the second highest in the world with the development of chronic hepatitis. Interferon-based combination therapy with ribavirin was the only available treatment until a few years back, with severe side-effects and high failure rates...
Main Authors: | Saba Khaliq, Syed Mohsin Raza |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-11-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1010-660X/54/5/80 |
Similar Items
-
Patients with Hepatitis C on Direct-Acting Antiviral Agents' Response to the Elimination Program in Dammam City within 2018-2020
by: Manal S. Fawzy, et al.
Published: (2022-09-01) -
Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan
by: M. N. Raza, et al.
Published: (2021-12-01) -
Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
by: Taisuke Imamura, et al.
Published: (2022-04-01) -
IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
by: Yadong Wang, et al.
Published: (2022-07-01) -
Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia
by: Mona H. Ismail
Published: (2024-01-01)